The 1-3-6 Rule: Building a Newborn Hearing Screening Program

Absolutely. Chronic myeloid leukemia and even chronic kidney disease are not contraindications, because CML is an indolent, slow-moving disease. As long as the patient is medically stable and vaccinated beforehand, implantation can significantly improve their social interaction and quality of life.

Programming is now available online because most modern devices have built-in Bluetooth. An audiologist can connect through an app on a laptop or phone and wirelessly program or calibrate the device remotely, in much the same way as this Zoom masterclass, without the patient needing to travel back.

In India, cochlear implants are not covered by insurance, and the device is expensive, so CSR funds and government programs are used to support Indian families. Nothing equivalent currently exists for international patients. Paid out of pocket, surgery including the device starts at around 14,000 US dollars and can go up to 36,000 US dollars for high-end models, with cost driven mainly by MRI-compatible magnet strength, auto-programming that adjusts to noise every few seconds, and built-in Bluetooth.

No. Implant companies design the internal device to stay compatible even as external technology advances. The first person implanted with a cochlear device, in 1984, is still using that original internal component 42 years later, having only upgraded the external processor along the way.

The internal device is designed to last a lifetime and does not normally require replacement, barring a major accident. The external processor is upgradeable and generally lasts 5 to 7 years, and patients tend to upgrade whenever a company introduces new technology, such as AI-based features.

Screen for hearing loss by one month of age, confirm a diagnosis by three months, and begin intervention by six months. Each step is a deadline rather than a suggestion, since the value of early detection decays with every month it is delayed.

Left unscreened, a child with hearing loss is often not diagnosed until age two, by which point much of the window during which the brain is most receptive to language has already closed.

Otoacoustic emissions testing is the primary screening tool. It is non-invasive, painless, portable and takes under a minute: a healthy cochlea's inner hair cells emit sound waves back to the testing device, and their absence is the signal that something needs a closer look.

The next step is a full diagnostic battery, including auditory brainstem response testing, ASSR, and behavioral or visual response audiometry.

High-risk infants, including those with a NICU stay, neonatal jaundice, meningitis, maternal CMV infection, a family history of hearing loss, prematurity, seizures, exposure to ototoxic drugs, or a syndromic appearance. Targeting this group captures a disproportionate share of cases even where a universal program is not yet feasible.